+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Should we embrace new drugs with open arms? Experience from a community-based, open-arm, randomized clinical trial of combination antiretroviral therapy in advanced HIV disease



Should we embrace new drugs with open arms? Experience from a community-based, open-arm, randomized clinical trial of combination antiretroviral therapy in advanced HIV disease



Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 13(5): 422-426



The effect of an open arm in the enrollment to a randomized clinical trial comparing zidovudine (ZDV) plus didanosine (ddI) versus ZDV plus zalcitabine (ddC) was assessed. HIV-infected individuals were eligible to participate in this protocol if they were ddI and ddC naive, had CD4 counts of 50-350/mm3, and were residents of the province of British Columbia. Participating individuals could choose between open-label ZDV/ddI, ZDV/ddC, or randomization to open-label ZDV/ddI or ZDV/ ddC. Study drugs were made available free of charge for all participants through a centralized drug distribution system. There is no other source of these drugs in the province. Primary care physicians were required to renew the patient's prescription every 2 months. Enrollment was initiated in November 1992 and was closed in March 1994 when the randomized arm of the protocol met the predetermined target sample size of 120 evaluable participants. A total of 582 patients received combination therapy in the province through this protocol: 138 (28%) enrolled in the randomized arm and 444 (76%) in the open arm. In the latter group, 320 (72%) were initially prescribed ZDV/ddI and 124 (28%) were prescribed ZDV/ddC. The enrollment rate was strikingly higher in the open arm, with 168 patients enrolled in the first 2 months compared with 138 patients enrolled in the randomized arm over 17 months. Of the 78 study physicians, 69 enrolled patients in the open arm and 23 enrolled patients in the randomized arm of the study. Experienced physicians were more likely to refer patients for randomization (p = 0.025). No statistically significant differences were observed between patients enrolled in either study arm. Our results illustrate the challenge posed to recruitment into clinical trials by the coexistence of an open arm. This is despite the noncoercive, open-label and community-based nature of our randomized protocol and the high priority given to it by a variety of local and national organizations. It is clear that an increased commitment by all interested parties will be required if randomized clinical trials are to be carried out with coexistent open arms.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 002956993

Download citation: RISBibTeXText

PMID: 8970468


Related references

Should we embrace new drugs with open arms? Experience within the community based, open arm, randomized study of ZDV/ddI verse ZDV/ddC. AIDS 8(Suppl. 4): S25, 1994

A community based, open arm, randomized study of ZDV/ddI vs ZDV/ddC Should we embrace new drugs with open arms?. TENTH INTERNATIONAL CONFERENCE ON AIDS, INTERNATIONAL CONFERENCE ON STD Tenth International Conference on AIDS and the International Conference on STD, Vol 2; The global challenge of AIDS: Together for the future : 2) 36, 1994

Combination therapy for advanced HIV disease A community based, open arm, open label, randomized study of the laboratory effects of ZDV/ddI vs ZDV/ddC. Clinical and Investigative Medicine 16(4 Suppl. ): B20, 1993

AIDS trials, civil liberties and the social control of therapy: should we embrace new drugs with open arms?. Cmaj 142(10): 1057-1062, 1990

AIDS trials, civil rights, and the social control of therapy: Should we embrace new drugs with open arms?. Controlled Clinical Trials 11(4): 258-0, 1990

Should we embrace new drugs with open arms?. AMERICAN SOCIETY FOR MICROBIOLOGY Author Human retroviruses and related infections : 125, 1995

Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial. Lancet 385(9983): 2173-2182, 2015

Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: a prespecified subgroup analysis of a community-based, randomized, open-label trial. Clinical Therapeutics 30(4): 661-672, 2008

An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial. Controlled Clinical Trials 24(4): 481-500, 2003

Efficacy and safety of artemisinin-based combination therapy and chloroquine with concomitant primaquine to treat Plasmodium vivax malaria in Brazil: an open label randomized clinical trial. Malaria Journal 17(1): 45, 2018

Phase II, Randomized, Open-Label, Community-Based Trial to Compare the Safety and Activity of Combination Therapy With Recombinant Interferon-α2b and Zidovudine Versus Zidovudine Alone in Patients With Asymptomatic to Mildly Symptomatic HIV Infection. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 20(3): 245-254, 1999

Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial. Journal of Acquired Immune Deficiency Syndromes 78(1): 54-61, 2018

The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: a post hoc analysis of an open-label community trial. Glaucoma Trial Study Group. Journal of Ocular Pharmacology and Therapeutics 16(1): 3-18, 2000

Effect of combination therapy with memantine and rivastigmine patch on agitation behavior in patients with mild-to-moderate Alzheimer's disease: A 24-week prospective, multicenter, randomized, open-label clinical trial. Alzheimer's and Dementia 6(4): S550-S551, 2010

Effects of varenicline therapy in combination with advanced behavioral support on smoking cessation and quality of life in inpatients with acute exacerbation of COPD, bronchial asthma, or community-acquired pneumonia: A prospective, open-label, preference-based, 52-week, follow-up trial. Chronic Respiratory Disease 15(2): 146-156, 2018